KKR and Ajax Health have announced the formation of FlowMod, a new medical device platform focused on developing a system for treating heart failure. FlowMod is the result of a collaboration between Boston Scientific, Ajax Health, and KKR, leveraging intellectual property from Boston Scientific to accelerate clinical validation and regulatory approval for a new heart failure treatment. The condition affects 64 million people worldwide.

Duke Rohlen, CEO of Ajax Health, highlighted the opportunity to introduce a differentiated solution for interventional heart failure treatment. Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR, emphasized the firm's commitment to advancing innovative medical technology.

FlowMod will be led by Dr. Philippe Marco, who previously served as President and Chief Operations Officer of Epix Therapeutics and CV Ingenuity, both Ajax-led companies that received pre-market approval for cardiovascular devices. KKR is investing in FlowMod through its KKR Health Care Strategic Growth Fund II, a $4 billion fund dedicated to high-growth health care companies.